Abstract
Ergot-induced disease in humans was known long before Biblical times and has been the root cause for countless human epidemics spanning from the early fourteenth century to the late sixteenth century. In contrast, many of these same ergot alkaloids have been utilized for their medicinal properties to mitigate migraine headaches and have had indications as anti-carcinogens. Although ergot alkaloids have been used for centuries by humans, basic pharmacokinetic data has not been documented for clinical disease in livestock. Consequently, a threshold dose and accurate dose-response data have yet to be established. Throughout the past several years, new detection techniques have emerged to detect these alkaloids at the parts per billion (ppb) level which has allowed for new efforts to be made with respect to determining threshold levels and making accurate clinical diagnoses in affected animals. This perspectives article provides a critical initial step for establishing a uniform interpretation of ergot toxicosis from limited existing data.
Introduction
Ergot alkaloids are made as secondary metabolites of fungi. Their production occurs in the sclerotia of several species of the genus Claviceps, the most common being Claviceps purpurea. These compounds belong to the family of indole alkaloids, one of the ten classes of alkaloids that pharmacologists have defined from plant secondary metabolites. Lysergic acid, a tetracycline ergoline ring system, is a common structure to all of the ergot alkaloids (Krska et al., ). The chemical structure of ergotamine, the most commonly found ergot alkaloid and the one responsible for the clinical disease known as ergot, has been documented in a classic text (Matossian, ; Bennett and Bentley, ; Council for Agricultural Science and Technology, ). Other major alkaloids detected in ergot sclerotia include ergocornine, ergocristine, ergosine, and ergonovine, and α-ergocryptine (Krska et al., ; Wallwey and Li, ; Takach and Young, ; also see Figure 1, the chromatogram).
Figure 1
Historically, ergot alkaloids have had a large impact on societies. They are likely the cause for the last of the 10 plagues of Egypt; it is believed that many of the oldest sons succumbed following the opening of grain and storage facilities whose contents were contaminated by the Claviceps fungi (Marr and Malloy,
Currently, modern grain cleaning techniques have eliminated ergotism as a human disease, but it remains a significant and devastating disease in the veterinary field primarily affecting sheep, cattle, pigs, and chickens. Clinical signs of ergotism in animals include gangrenous extremities, abortion, convulsions, agalactia, and ataxia (Lorenz and Hoseney,
In the United States, there is no regulatory limit defined for ergot alkaloids in grain. In Europe, while there are discussions on establishing legal limits, the European Food Safety Agency (EFSA) at this time has not recommended a limit other than 0.03–3.6 and 0.6 μg/kg b.w. per day for children and adults, respectively (European Food Safety Authority,
Two types of ergotism have been described: gangrenous (vasoconstrictive) and convulsive (neurological and abortogenic) (da Rocha et al.,
Table 1
| Alkaloid | Onset (M)b | EC50 (M) | EMAX (%) | Ergotamine equivalence level |
|---|---|---|---|---|
| Ergovaline | 1 × 10−8 | 4.0 × 10−6 ± 1.5 × 10−6 | 104.1 ± 6.0 | 1 |
| Ergotamine | 1 × 10−8 | 4.0 × 10−6 ± 1.5 × 10−6 | 104.1 ± 6.0 | 1 |
| Ergonovine | 1 × 10−7 | 3.4 × 10−6 ± 8.8 × 10−7 | 68.5 ± 4.1 | 0.1 |
| Ergocristine | 1 × 10−7 | 5.6 × 10−6 ± 1.3 × 10−6 | 45.5 ± 4.5 | 0.1 |
| Ergocornine | 1 × 10−7 | 4.0 × 10−5 ± 2.3 × 10−5 | 57.2 ± 9.9 | 0.1 |
| α-Ergocryptine | 1 × 10−6 | 5.4 × 10−6 ± 1.2 × 10−6 | 42.9 ± 4.1 | 0.01 |
| Lysergic acid | 1 × 10−5 | 5.5 × 10−5 ± 2.3 × 10−5 | 22.6 ± 4.1 | 0.001 |
Concentration at onset of contractile response, half maximal effective concentration or potency (EC50), and the maximal response or efficacy (EMAX) of ergot alkaloids in bovine lateral saphenous veinsa.
Taken from Klotz et al. (
Expressed as a percent of norepinephrine maximum, which was a 1 × 10−4 M norepinephrine reference addition. Onset is normalized to the closest order of magnitude.
The Endophyte Service Laboratory (ESL) (Craig et al.,
Methods
Extraction of the ergot alkaloids
A method for extraction of ergot alkaloids from plant material was developed based on previous studies, for subsequent analysis by HPLC-fluorescence (Rottinghaus et al., 1991; Hill et al., 1993; Craig et al.,
HPLC-fluorescence analysis for ergot alkaloids
Reverse-phase HPLC analysis is coupled with fluorescence detection (excitation and emission wavelengths of 250 nm and 420 nm, respectively) and a gradient run at 0.9 mL/min. Mobile phases of 1 mM ammonium carbonate (A) and ACN (B) were programmed as follows: equilibrate from 0 to 5 min at 75% A, then decrease linearly to 65% A from 5 to 15 min, hold at 65% A from 15 to 20 min, then decrease linearly to 25% A from 20 to 25 min. A Gemini 3.0 μC18 110Å (Phenomenex, Torrance, CA) column was used in conjunction with a guard column cartridge of similar packing. Figure 1 shows an example of a HPLC-fluorescence chromatogram for ergonovine, ergosine, ergotamine, ergocornine, α-ergocryptine, and ergocristine produced using this assay. [Ergonovine and the epimers of the other ergot alkaloids are not retained by the Ergosil® SPE columns (reference Krska et al.,
What we know about vasoconstriction and abortion from ergot alkaloids
Using the data presented in Klotz et al. (
As Table 1 emphasizes, ergovaline and ergotamine have equal sensitivity for vasoconstriction, whereas ergonovine, ergocristine, and ergocornine are about one-tenth as powerful. Pharmacologically, the half-maximal concentration (EC50) and the onset concentration are measures of a compound's potency (the lower the concentration the more potent the compound); ergotamine and ergovaline are identical in this aspect. The onset of vasoconstriction is reported in concentration (moles/L), and is viewed as the best indicator of toxicosis when evaluating levels in feedstuffs. Interpreting the chromatogram in Figure 1 in relation to the additive effects of all ergot alkaloids present is performed by utilizing a multiplicative factor in front of various alkaloids; therefore, 10 ergonovine molecules are equally vasoconstrictive to one ergovaline molecule. More recently, Klotz et al. (
Table 2
| Case number | Total ergot level observed (ppb)a | Ergotamine equivalence level (ppb) | Weather conditions | Clinical signs observed |
|---|---|---|---|---|
| a | 473 | 473 | −20°C, Canada, February | Tail loss |
| b | 1500 | 415 | 1°C, Oregon, December | Moderate lameness |
| c | 2909 | 466 | −2°C, Idaho, January | Decreased feed intake |
| d | 3555 | 778 | −5°C, E. Oregon, February | Early term abortions, low milk yield |
| e | 5999 | 626 | −5°C, Idaho, January | No feed consumption |
| f | 11,538 | 1161 | −4°C, Canada, April | Sloughing of hooves |
| g | 54,916 | 3728 | 1°C, Oregon, January | Early term abortions |
| h | 62,245 | 10,124 | −1°C, Idaho, January | Hooves sloughing completely off |
Clinical evaluation of ergot toxicosis in cattle with ergotamine equivalence levels (ppb) in feed on a dry weight basis.
Includes ergonovine, ergosine, ergotamine, ergocornine, α-ergocryptine, and ergocristine.
Correlation of ergot toxins with clinical disease
The alkaloids that cause fescue foot and summer slump syndrome are produced by fungi in pasture grasses. Because of similar vasoconstrictive abilities of ergovaline and ergotamine, we have correlated some of the studies done with fescue with what we have seen from clinical cases with ergot. Field and barn studies of natural fescue foot and herds have been conducted (Oliver,
In Table 2, column 2 represents the total alkaloids observed, which include a summation of all six ergot alkaloids. Since different alkaloids have different vasoconstrictive onset values, column 3 relates the six alkaloids (Table 1) back to “ergotamine equivalents.” Therefore, ergotamine equivalents are correlated to clinical signs (column 5).
Eight examples of clinical cases associated with feed samples submitted to the ESL by veterinarians suspecting ergot toxicosis are shown to illustrate typical cases that have been seen. The ESL consults with veterinarians and evaluates all aspects of the case to determine if testing of feed samples is warranted. If so, results are often discussed with the client to ensure that proper measures are taken to resolve ergot toxicosis. Five to ten years ago the ESL would observe ergot cases approximately once per month; however, this has progressed to several cases per week and sometimes multiple cases each day in recent years despite maintaining approximately the same number of total samples tested. Our worst toxicosis cases have been in cattle and horses. The increase in cases seen in the Pacific Northwest and throughout the country is likely due to climate change or the lack of field burning that has been phased out throughout the years. The stoppage of burning has greatly reduced the ability to destroy C. purpurea by fire.
Evaluation of the cases included in Table 2 is as follows:
The following cases in cattle involved pellets as nearly 100% of the provided feed source, with the exclusion of case b, which used a grass seed sample. Pellets were usually a combination of grass seed with additional alfalfa or other hay sources mixed in. In cases f and h, cattle had exposure to overgrazed pasture, and it is estimated that little nutrition came from the pasture sources. In both cases, the pellet mixture comprised most of the usable diet.
The first case (a) presents an ergotamine level of nearly 500 parts per billion (ppb). This case originated in February when the colder weather prompted vasoconstriction in the extremities, specifically, the tissue around the tail to become necrotic. No sloughing of ears were observed nor reported in this particular case.
The second case (b) reported 1500 ppb ergot alkaloids and occurred in December as the feed bunks were being cleaned out. There was moderate lameness and some necrosis about the feet. The 1500 ppb consisted of ergotamine and ergocornine, resulting in a lower ergotamine equivalence level (415 ppb) that was similar to case (a).
The third case (c) revealed approximately 2900 ppb ergot alkaloids in pellets which triggered a decreased consumption in feed, as well as a necrotic area around the coronet band of the hoof. This outcome was observed in steers in January. Ergotamine, ergocornine, and ergocryptine were found in the feed. The ergotamine equivalence level (466 ppb) illustrated similarities to that of case (a).
The fourth case (d) presented nearly 3500 ppb ergot alkaloids and took place in February. This case showed greater severity of clinical signs, i.e., term abortions, agalactia, and reduced milk production in the dairy herd. This case had a 778 ppb ergotamine equivalence level.
The fifth case (e) presented itself in January and had a total ergot alkaloid concentration of 6000 ppb. The animals refused to consume any feed, resulting in near starvation. This case was composed of very little ergotamine and mostly other ergot alkaloids, which dramatically brought the ergotamine equivalence level down to 626 ppb.
The sixth case (f) occurred during April, with ergot alkaloid levels measuring almost 12,000 ppb. The steers exhibited sloughing of the hooves, tails, and ears. So many animals sloughed their hooves that approximately 40% of the herd had to be terminated. This case consisted of multiple ergot alkaloids and had an ergotamine equivalence level of approximately 1000 ppb.
The seventh case (g) was the second highest case of total ergot alkaloids (54,916 ppb) that we have observed and occurred in January. Though the weather was fairly warm and dry, there were early term abortions in a high percentage of the cow-calf operation. Approximately 45–47 of the 59 animals that were pregnant had early term abortions over a 2 week period. This case had an approximate 4000 ppb ergotamine equivalence level.
The eighth (h) and final case entailed the observance of cattle during January in the northern region of the United States. This case produced approximately 62,000 ppb of total ergot alkaloids. The clinical consequences of the ergot alkaloids resulted in 3/4 of the cow's hooves to slough off, after which the animals had to be sacrificed. This case consisted of both ergotamine and other ergot alkaloids, and had an ergotamine equivalence level to approximately 10,000 ppb. Although the weather was warm, the high concentration of ergot alkaloid induced enough vasoconstriction to clinically affect the animals.
The bioavailability and pharmacokinetic data of ergot alkaloids in cattle are limited and affected by many different factors. However, using the highest and the lowest dietary ergotamine concentrations reported in Table 2, calculations were done to illustrate a theoretical relationship with the ergotamine concentration in a feedstuff and a maximum potential concentration in blood. A feedstuff containing the lowest concentration of 473 ppb (case a) or 0.473 mg/kg ergotamine fed to a 500 kg cow consuming 2.5% of BW will consume a total of 5.9 mg of ergotamine per day. Assuming that the ergotamine is 100% bioavailable from the feedstuff (not always the case as this is negatively correlated with the maturity of the feedstuff), 100% absorbed (not always the case, as these compounds are likely biotransformed by gut microbes prior to absorption), 100% bioavailable in the blood (assuming negligible bioaccumulation in tissues or initial hepatic detoxification) and total blood volume of 55 mL/kg of BW, a maximum ergotamine concentration ever reaching the blood would be 0.215 μg ergotamine/mL of blood. Although this is far below the EC50 reported for ergotamine in Table 1 of 4 × 10−6 M or an approximate of 2.32 μg of ergotamine/mL in blood, it is much higher than the corresponding onset concentration for ergotamine of 1 × 10−8 M or 0.005 μg /mL. If we substituted the highest reported ergotamine concentration in Table 2 (case h), the maximum concentration of ergotamine that could ever reach the blood is 4.6 μg /mL. This is twice the concentration of the EC50 of ergotamine and could easily explain the severe clinical signs observed.
The data that resulted from these clinical cases illustrate that ergot alkaloids can cause vasoconstriction and deleterious consequences regardless of seasonal conditions (Egert et al.,
What should be done in future studies?
Though this disease has been known for hundreds of years, only a paltry amount of information is available to accurately diagnose disease at a clinical level (where animal production is affected and animal welfare becomes a concern). The first step in expanding this information should be establishing the threshold level in different species, particularly cattle and horses that could be exposed to ergot alkaloids in their feed. It should be noted that overseas, camels, goats, and sheep are also frequently exposed to these toxic alkaloids. The second step is to establish other bio-indicators of clinical disease other than prolactin levels, weight gain, and some of the more classical animal observances. Lastly, the vasoconstrictive and convulsive effects and their subsequent clinical consequences need to be separated.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Statements
Acknowledgments
Special thanks and recognition go out to Avalon McKune and McKenzie Hughes for helping in the progress of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
BennettJ. W.BentleyR. (1999). Pride and prejudice: the story of ergot. Perspect. Biol. Med. 42, 333–355. 10.1353/pbm.1999.0026
2
BlodgettD. J. (2001). Fescue toxicosis. Vet. Clin. North Am. Equine Pract. 17, 567–577.
3
BrendemuehlJ. P.BoosingerT. R.BransbyD. I.SchumacherJ. (1995). The effect of short term exposure to and removed from the fescue endophyte Acremonium coenophialum on pregnant mares and foal viability. Biol. Reprod. Mono1, 61–67.
4
Council for Agricultural Science and Technology. (2003). Mycotoxins: Risks in Plant, Animal, and Human Systems. Ames, IA.
5
CraigA. M.BilichD.HovermaleJ. T.WeltyR. E. (1994). Improved extraction and HPLC methods for ergovaline from plant material and rumen fluid. J. Vet. Diagn. Invest. 6, 348–352. 10.1177/104063879400600311
6
CraigA. M.BlytheL. L.DuringerJ. M. (2014). The role of the Oregon state university endophyte service laboratory in diagnosing clinical cases of endophyte toxicosis. J. Agric. Food Chem. 62, 7376–7381. 10.1021/jf5027229
7
da RochaM. E.da Chagas Oliveira FreireF.Feitosa MaiaF. E.Florindo GuesedM. I.RondinaD. (2014). Mycotoxins and their effects on human and animal health. Food Control36, 159–165. 10.1016/j.foodcont.2013.08.021
8
DuringerJ. M.MurtyL. D.CraigA. M. (2012). Endophyte mycotoxins in animal health, in Phytchemicals, Plant Growth, and the Environment, ed GangD. R. (New York, NY: Springer), 37–58. 10.1007/978-1-4614-4066-6_3
9
DyerD. C. (1993). Evidence that ergovaline acts on serotonin receptors. Life Sci. 53, 223–228. 10.1016/0024-3205(93)90555-H
10
EckertH.KiechelJ. R.RosenthalerJ.SchmidtR.SchreierE. (1978). Biopharmaceutical aspects: analytical methods, pharmokinetics metabolism and bioavailability, in Ergot Alkaloids and Related Compounds, eds BerdeB.SchildH. O. (Berlin: Springer Verlag), 719–803.
11
EgertA. M.KimD. H.SchrickF. N.HarmonD. L.KlotzJ. L. (2014). Dietary exposure to ergot alkaloids decreases contractility of bovine mesenteric vasculature. J. Anim. Sci. 92, 1768–1779. 10.2527/jas.2013-7141
12
European Food Safety Authority. (2012). Scientific opinion on ergot alkaloids in food and feed. EFSA panel on contaminants in the food chain (CONTAM). Eur. Food Saf. Auth. J. 10, 2798. 10.2903/j.efsa.2012.2798
13
FooteA. P.HarmonD. L.BrownK. R.StricklandJ. R.McLeodK. R.BushL. P.et al. (2012). Constriction of bovine vasculature caused by endophyte-infected tall fescue seed extract is similar to pure ergovaline. J. Anim. Sci. 90, 1603–1609. 10.2527/Jas.2011-4513
14
HillN. S.RottinghausG. E.AgeeC. S.SchultzL. M. (1993). Simplified sample preparation for HPLC analysis of ergovaline in tall fescue. Crop Sci. 33, 331–333. 10.2135/cropsci1993.0011183X003300020024x
15
KlotzJ. L.AikenG. E.JohnsonJ. M.BrownK. R.BushL. P.StricklandJ. R. (2013). Antagonism of lateral saphenous vein serotonin receptors from steers grazing endophyte-free, wild-type, or novel endophyte-infected tall fescue. J. Anim. Sci. 91, 4492–4500. 10.2527/jas.2012-5896
16
KlotzJ. L.BushL. P.SmithD. L.ShaferW. D.SmithL. L.ArringtonB. C.et al. (2007). Ergovaline-induced vasoconstriction in an isolated bovine lateral saphenous vein bioassay. J. Anim. Sci. 85, 2330–2336. 10.2527/jas.2006-803
17
KlotzJ. L.BushL. P.StricklandJ. R. (2011). A vascular contractility bioassay using bovine right ruminal artery and vein. J. Anim. Sci. 89, 1944–1951. 10.2527/jas.2010-3532
18
KlotzJ. L.BushL. P.SmithD. L.ShaferW. D.SmithL. L.VevodaA. C.et al. (2006). Assessment of vasoconstrictive potential of D-lysergic acid using an isolated bovine lateral saphenous vein bioassay. J. Anim. Sci. 84, 3167–3175. 10.2527/jas.2006-038
19
KlotzJ. L.KirchB. H.AikenG. E.BushL. P.StricklandJ. R. (2008). Effects of selected combinations of tall fescue alkaloids on the vasoconstrictive capacity of fescue-naive bovine lateral saphenous veins. J. Anim. Sci. 86, 1021–1028. 10.2527/jas.2007-0576
20
KlotzJ. L.KirchB. H.AikenG. E.BushL. P.StricklandJ. R. (2010). Contractile response of fescue-naive bovine lateral saphenous veins to increasing concentrations of tall fescue alkaloids. J. Anim. Sci. 88, 408–415. 10.2527/jas.2009-2243
21
KrskaR.CrewsC. (2008). Significance, chemistry and determination of ergot alkaloids: a review. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess25, 722–731. 10.1080/02652030701765756
22
KrskaR.StubbingsG.MacarthurR.CrewsC. (2008). Simultaneous determination of six major ergot alkaloids and their epimers in cereals and foodstuffs by LC–MS–MS. Anal. Bioanal. Chem. 391, 563–576. 10.1007/s00216-008-2036-6
23
LarsonB. T.HarmonD. L.PiperE. L.GriffisL. M.BushL. P. (1999). Alkaloid binding and activation of D2 dopamine receptors in cell culture. J. Anim. Sci. 77, 942–947.
24
LorenzK.HoseneyR. C. (1979). Ergot on cereal grains. CRC Crit. Rev. Food Sci. Nutr. 11, 311–354. 10.1080/10408397909527267
25
MarinS.RamosA. J.Cano-SanchoG.SanchisV. (2013). Mycotoxins: occurrence, toxicology, and exposure assessment. Food Chem. Toxicol. 60, 218–237. 10.1016/j.fct.2013.07.047
26
MarrJ. S.MalloyC. D. (1996). An epidemiologic analysis of the ten plagues of Egypt. Caduceus12, 7–24.
27
MatossianM. A. K. (1989). Poisons of the Past: Molds, Epidemics, and History. New Haven, CT: Yale University Press.
28
MiyazakiS. (2004). Effects of mycotoxins to livestock: could there be industrial and public health problems in Japan?Mycotoxins54, 113–117. 10.2520/myco.54.113
29
OliverJ. W. (2005). Pathophysiologic response to endophyte toxins, in Neotyphodium in Cool-season Grasses, eds RobertsC. A.WestC. P.SpiersD. E. (Ames, IA: Blackwell Publishing), 291–304. 10.1002/9780470384916.ch13
30
OliverJ. W.StricklandJ. R.WallerJ. C.FribourgH. A.LinnabaryR. D.AbneyL. K. (1998). Endophytic fungal toxin effect on adrenergic receptors in lateral saphenous veins (cranial branch) of cattle grazing tall fescue. J. Anim. Sci. 76, 2853–2856.
31
PanaccioneD. G.BeaulieuW. T.CookD. (2014). Bioactive alkaloids in vertically transmitted fungal endophytes. Funct. Ecol. 28, 299–314. 10.1111/1365-2435.12076
32
PanaccioneD. G.RyanK. L.SchardlC. L.FloreaS. (2012). Analysis and modification of ergot alkaloid profiles in fungi, in Natural Product Biosynthesis by Microorganisms and Plant, Pt A Methods in Enzymology, ed HopwoodD. A. (San Diego: Elsevier Academic Press Inc), 267–290. 10.1016/B978-0-12-394290-6.00012-4
33
PesqueiraA.HarmonD. L.BrancoA. F.KlotzJ. L. (2014). Bovine lateral saphenous veins exposed to ergopeptine alkaloids do not relax. J. Anim. Sci. 92, 1213–1218. 10.2527/jas.2013-7142
34
RichardJ. L. (2007). Some major mycotoxins and their mycotoxicoses–an overview. Int. J. Food Microbiol. 119, 3–10. 10.1016/j.ijfoodmicro.2007.07.019
35
RichardJ. L. (2012). Mycotoxins - an overview, in Guide to Mycotoxins, ed BinderE. M. (Leicestershire: Anytime Publishing Services), 1–47.
36
RottinghausG. E.GarnerG. B.CornellC. N.EllisJ. L. (1991). HPLC method for quantitating ergovaline in endophyte-infested tall fescue: seasonal variation of ergovaline levels in stems with leaf sheaths, leaf blades, and seed heads. J. Agric. Food Chem. 39, 112–115. 10.1021/jf00001a022
37
RottinghausG. E.SchultzL. M.RossP. F.HillN. S. (1993). An HPLC method for the detection of ergot in ground and pelleted feeds. J. Vet. Diagn. Invest. 5, 242–247. 10.1177/104063879300500216
38
SaigaS. (1998). Frequent occurences of cattle poisoning through endophyte-infected hay. Livest. Tech. 21–25.
39
SchöningC.FliegerM.PertzH. H. (2001). Complex interaction of ergovaline with 5-HT2A, 5-HT1B/1D, and alpha1 receptors in isolated arteries of rat and guinea pig. J. Anim. Sci. 79, 2202–2209.
40
TakachJ. E.YoungC. A. (2014). Alkaloid genotype diversity of tall fescue endophytes. Crop Sci. 54, 667. 10.2135/cropsci2013.06.0423
41
Tor-AgbidyeJ.BlytheL. L.CraigA. M. (2001). Correlation of endophyte toxins (ergovaline and lolitrem B) with clinical disease: fescue foot and perennial ryegrass staggers. Vet. Hum. Toxicol. 43, 140–146.
42
WallweyC.LiS.-M. (2011). Ergot alkaloids: structure diversity, biosynthetic gene clusters and functional proof of biosynthetic genes. Nat. Prod. Rep. 28, 496–510. 10.1039/c0np00060d
43
WeltyR. E.CraigA. M.AzevedoM. D. (1994). Variability of ergovaline in seeds and straw and endophyte infection in seeds among endophyte-infected genotypes of tall fescue. Plant Dis. 78, 845–849. 10.1094/PD-78-0845
Summary
Keywords
ergot, ergotism, ergovaline, ergotamine, ergocornine, clinical disease, saphenous vein, cattle
Citation
Craig AM, Klotz JL and Duringer JM (2015) Cases of ergotism in livestock and associated ergot alkaloid concentrations in feed. Front. Chem. 3:8. doi: 10.3389/fchem.2015.00008
Received
18 September 2014
Accepted
22 January 2015
Published
18 February 2015
Volume
3 - 2015
Edited by
Darrin Smith, Eastern Kentucky University, USA
Reviewed by
Youngjoo Kwon, Ewha Womans University, South Korea; Cynthia L. Gaskill, University of Kentucky, USA
Copyright
© 2015 Craig, Klotz and Duringer.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: A. Morrie Craig, Department of Biomedical Sciences, College of Veterinary Medicine, Oregon State University, 105 Magruder Hall, Corvallis, OR 97331,USA e-mail: a.morrie.craig@oregonstate.edu
This article was submitted to Chemical Biology, a section of the journal Frontiers in Chemistry.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.